Our editorial team dissects the latest developments in the ongoing story of how evolving US tariffs could impact the ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Eisai and Biogen have received marketing authorisation from the European Commission (EC) for Leqembi (lecanemab) to treat Alzheimer's.

Mural Oncology is halting development of its lead IL-2 therapy and enacting major layoffs after its second trial failure this ...

Irish medical and pharmaceutical exports to the US have seen a surge, with a year-on-year increase above 450% in February ...

AD is a growing market with an impressive pipeline of new products from current and future players in the field.

Boehringer and Cue Biopharma have entered a strategic research partnership and licence agreement for the latter’s CUE-501.

J&J is projecting a $400m hit due to US tariffs in 2025, but reaffirmed its profit outlook while raising its sales forecast.